YoungCareerResearchers_1

Young Individual Research Grant (YIRG) Awardees

Samudin Firdaus - STRUCTURE AND DYNAMICS OF MACROMOLECULAR COMPLEXES

We use integrative molecular modelling and molecular dynamics simulation to learn how large biological macromolecules such as antibodies and protein complexes behave in their native environment, which can subsequently be exploited for therapeutic interventions.

IgM antibodies in cancer therapeutics and detection

Monoclonal antibodies have been an instrumental part of standard chemotherapy regiments. Apart from cancer therapeutics, antibodies also show great potential in diagnosis due to their remarkable specificity. To date, most antibodies used in cancer therapy and diagnosis belong to the immunoglobulin (Ig) isotype IgG. The use of other antibody isotypes including IgM remains largely unexplored despite their potential benefits. Unlike IgG, which has two antigen-binding fragment (Fab) regions, IgM has up to twelve Fabs and thus, in principle, a higher binding avidity to its antigen. Due to its large size, IgM can also form bridges between distant antigens on different cancer cells to trigger agglutination, which is beneficial to neutralise metastatic cells, and for enrichment of circulating tumour cells in blood samples for diagnosis. IgM is therefore an attractive candidate for future cancer treatment and diagnostic tools.

Our collaborator from APD lab in EDDC showed that the IgM form of Pertuzumab and Trastuzumab, monoclonal antibodies used to treat breast cancer, have different binding avidities to their target, human epidermal growth factor receptor 2 (HER2). We built integrative models of full-length Pertuzumab and Trastuzumab IgM hexamers bound to the HER2 extracellular domains (ECD). Our models revealed that the Pertuzumab IgM hexamer can utilize all its Fab domains to bind to twelve HER2 ECDs simultaneously. The binding was shown to be stable in subsequent simulations. Conversely, we found that the Trastuzumab IgM hexamer was not able to bind multiple HER2 ECDs due to steric clashes caused by the large globular domain of the latter (Figure 1). This computational prediction was then validated by cell count assays using HER2 over expressing cell lines showing that Pertuzumab IgM was better than IgG at inhibiting cell proliferation, whereas the opposite trend prevailed for Trastuzumab.

BII_EarlyCareerResearchers-SDMC-Figure-1

Figure 1 – Modelling the interactions of Pertuzumab (A) and Trastuzumab (B) IgM with HER2 ECD. Antibodies are shown in ribbon representation with the heavy chains shown in green and the light chains shown in orange. Twelve copies of HER2 ECD are shown in surface representation and coloured purple and pink. Enlarged images of one IgM subunit is shown on the right and steric clashes in Trastuzumab are highlighted by the black circle.

Our study highlights the importance of understanding the molecular details of antigen-antibody interactions for isotype and epitope selection in engineering therapeutic antibodies. Our group has been awarded the 2021 AME YIRG grant to expand this study to other monoclonal antibodies and cancer antigens.

Modelling and simulation of SARS-CoV-2 spike glycoprotein

The binding of spike (S) protein to human angiotensin converting enzyme 2 (ACE2) receptor is the primary cellular recognition mechanism of SARS-CoV-2. Understanding the dynamics of S protein is therefore essential for drug and vaccine development. We built a full-length model of the S protein with associated glycans and performed simulation in its native membrane environment. Our model shows good agreement with various experimental data and independently built models. In collaboration with the MSMD group in BII, we simulated the model with benzene probes to uncover cryptic pockets on the surface of the S protein (Figure 2). Remarkably, our simulations not only recapitulated known cryptic pockets identified by cryo-electron microscopy, but also revealed a potentially druggable site near the prevalent D614G mutation. We are currently performing virtual screening for compounds targeting this pocket.

BII_EarlyCareerResearchers-SDMC-Figure-2

Figure 2 – Benzene mapping on the SARS-CoV-2 spike protein. The figure shows the first and last snapshots of the simulation with S protein shown in pink, glycans in yellow, benzene molecules in dark green and membrane in grey. Enlarged image shows a novel potentially druggable pocket found nearby the multimodal loop 617-628, shown in cartoon representation in magenta.

Our model has also been used to predict how bacterial lipopolysaccharide (LPS) interacts with the S protein, in collaboration with the Schmidtchen lab in Lund, Sweden. We predicted an LPS binding site at the inter-protomeric groove nearby the S1/S2 cleavage site. The study provides molecular mechanisms linking SARS-CoV-2 infection and hyperinflammation observed in severe COVID-19 patients. Additionally, we also collaborated with the Crispin lab in Southampton, UK to understand how S proteins expressed from different labs around the world have a conserved glycosylation pattern. Our simulation of the S protein model with oligomannose glycans shows correlation between glycan processing enzyme accessibility to glycosylation site with the degree of oligomannose content.

HIV-1 Gag mutations and viral fitness

Synergistic mutations on HIV-1 protease and its substrate, the Gag polyprotein, drive drug resistance against protease inhibitors. Intriguingly, most Gag mutations occur outside of the cleavage site and the mechanism of how these mutations confer resistance is unknown. We built a model of the largest Gag proteolytic product consisting of six matrix (MA) trimers linked to a hexamer of capsid (CA) protein and simulated it with a model HIV-1 membrane (Figure 3).

BII_EarlyCareerResearchers-SDMC-Figure-3

Figure 3 – Simulation of HIV-1 Gag MA-CA complex. MA domain is shown in cyan, and the CA domain is shown green. The positions of clinically relevant non-cleavage site mutations are indicated by the red spheres. Protease protein is shown in pink, and the model membrane is shown in dark green.

We found that despite their distance to the cleavage site, some mutations can directly interact with cleavage site residues due to the contraction of the linkers between the MA and CA domains, thus potentially influencing the local environment for proteolysis. Mutations in the MA domain enriches lipids important for Gag targeting and assembly. Other mutations were shown to have positive impacts on cyclophilin A interaction and the stability of oligomeric interface. Collectively, our simulations provide molecular explanation of the far-reaching consequences of Gag mutations to the overall fitness of HIV-1 virus.

Su Tran-To Chinh - Algorithms & Models of Protein Machinery

We study protein complex behaviors by combining protein structural modeling and other computational algorithms, from which we search for the governing principles that may have driven the structural interactions.

Structural relationship of HIV-1 Protease Inhibitor (PI) resistant mutants

Based on the structural responses and viral fitness cost of the clinically reported HIV-1 protease mutations, we reported a PI resistance-related pathway that the protease might undertake to cross-resist among current PIs in the anti-retroviral therapy.

We found the structural rationale for the rapid development of cross-resistance among the seven clinically used PIs, e.g. Atazanavir (ATV), Darunavir (DRV), Indinavir (IDV), Lopinavir (LPV), Nelfinavir (NFV), Saquinavir (SQV), and Tipranavir (TPV). Among these, some PIs would be better used in clinical settings against naïve HIV-1 infections or when resistance has already been developed towards another PI.

Our findings suggest the use of LPV as the first line of PI in the current anti-retroviral therapy. In circumstances with the emergence of PI-resistant mutations, certain other drugs would be more useful in subsequent lines of treatment (Figure 1). Hence the study provides a structural understanding that may be useful to guide the clinical PI use in the therapy, aiding in drug selection to prolong the effectiveness of the given PI.

BII_Research-BMAD-AMPM-Figure-1

Figure 1 –The HIV-1 Protease Inhibitor (PI) resistance-related pathway that the viral protease might undertake to cross-resist among current PIs: Atazanavir (ATV, cyan), Darunavir (DRV, blue), Indinavir (IDV, red), Lopinavir (LPV, yellow), Nelfinavir (NFV, magenta), Saquinavir (SQV, green), and Tipranavir (TPV, purple).

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance

HIV-1 protease inhibitors against the viral protease are often hampered by drug resistance mutations in protease and in the protease substrate Gag (Figure 2A-B). To overcome this drug resistance, it may be more efficient to target Gag alongside with protease rather than targeting protease alone. To inhibit Gag, understanding of its drug resistance mutations and the corresponding structural changes on protease binding thus needs investigating.

While mutations on Gag have already been mapped to protease inhibitor resistance (Figure 2C), there remain many mutations, particularly those outside the Gag cleavage sites, that are not well-characterized. Through structural studies to unravel how Gag mutations contributes to protease drug resistance synergistically, it is thus possible to glean insights to design novel Gag inhibitors. In this review (Su et al., 2019), we discuss the structural role of both novel and previously reported Gag mutations in PI resistance, and how new Gag inhibitors can be designed.

BII_Research-BMAD-AMPM-Figure-2

Figure 2 – (a) Schematic relationship between Protease and its substrate Gag in HIV-1 (A,B) and their associated drug resistance mutations (C). Mutation hotspots are shown for both Gag and Protease, with Gag mutations following domain-color schemes: MA (red), CA (green), NC (magenta), and p6 (orange).

Non-canonical glutamine binding Ni2+ mechanism in IgE

The binding of nickel (Ni) by immune proteins can manifest as Type IV contact dermatitis and less frequently as Type I hypersensitivity. Both mechanisms remains unknown. Using Trastuzumab and Pertuzumab IgE variant models that have been investigated by the APD Lab, with whom we found that Ni2+ (in Ni-NTA) interacted non-canonically with glutamine stretches. These stretches are formed at the interfaces of the antibody heavy and light chains in a certain of the IgE variants.

BII_Research-BMAD-AMPM-Figure-3

Figure 3 – Ni2+ (in Ni-NTA) binds to a particularly formed glutamine stretch in Trastuzumab IgE (but not Pertuzumab IgE) due to varying structural arrangement of heavy and light chain domains of different IgE variants.

IgE complexes with peanut allergen and FcεRIα receptor

Our current project focuses on the whole allergen-IgE-FcεRIα system and their affinities to guide therapeutic interventions against peanut allergy. This work aims to study the IgE-mediated interaction mechanisms at the atomic level, combining computational structural modelling and experimental cross-linking Mass Spectrometry for validation (collaborating with the Kalisman Lab in the Hebrew University of Jerusalem and the APD Lab in EDDC).

Marzinek Jan [To be updated]

- To be updated -

Career Development Award (CDA) Awardees

Li Jianguo - Membrane Biophysics and Drug Delivery

Drug discovery is a tedious and complicate process, often with high attrition rate. To efficiently translate the fundamental knowledge to therapeutics, we combine computational modelling and simulations, in vitro and in vivo experiments to rationalize the drug development. Our current focuses are (i) development of next generation membrane active antibiotics against multi-drug resistant (MDR) bacteria; and (ii) understand the mechanism of membrane translocation of drug like molecules such as natural products, peptides etc.

Novel antibiotic development for treating MDR infections

Antibiotic resistance has become a global healthcare problem due to the overuse of antibiotics. Membrane-active antimicrobials are promising to tackle the problem of rapid increases in resistance. Unlike traditional antibiotics that target specific receptors which can be easily mutated, membrane-targeting antibiotics disrupt/perturb bacterial membranes, an essential component of the bacterial cell with low mutation rate, therefore have low tendency to develop resistance. Currently we are working on two main classes of membrane-active antimicrobials, antimicrobial peptides (AMP) and small synthetic antimicrobials. We have developed a multi-disciplinary approach for rational development of membrane active antibiotics, which includes: in silico modelling and simulations, in vitro validation and characterizations and in vivo evaluations (Figure 1). This platform enables us to gain insights from different angles and has been successful for rational development of membrane active antimicrobials.

BII_EarlyCareerResearchers-MBDD-figure1

Figure 1 – A multi-disciplinary platform for rational development of novel antibiotics against MDR infections.

Starting from human beta-defensin 3, we have developed a series branched lipo-peptide oligomers by covalent crosslinking peptide monomer through a branched lysine core. One of the peptides B2088 display excellent antimicrobial activity against MDR bacteria yet with low toxicity. Higher oligomer such as the peptide tetramer B4010 are also active against a panel of fungi and yeasts. These peptide oligomers were found to be able to disrupt the outer membrane of Gram negative bacteria and facilitate the translocation of traditional antibiotics into the bacterial cell. On the other hand, using the strategy of fragment based drug design, for the first time, we have proposed a pharmacophore model for the design of small molecule antibiotics targeting the bacterial inner membrane. Based on the pharmacophore model, we have synthesized a small library of semi-synthetic natural products that are active against a wide range of Gram positive bacteria. By combination of the outer membrane targeting peptide antibiotics and the inner membrane targeting semi-synthetic natural products, we developed combinational therapies (Figure 2) that are active against both Gram positive and Gram negative superbugs without inducing resistance, including the recently appeared mobile colistin resistant bacteria mcr-1.

BII_EarlyCareerResearchers-MBDD-figure2

Figure 2 – The development of combinational therapy for the treatment of MDR infections. The combinational therapy consists of a peptide based antibiotic permeabilizing the bacterial outer membrane and a small molecule antibiotic disrupting the bacterial inner membrane. With both membrane being targeted, no resistance can develop.

Drug delivery across the cytoplasmic membrane

Membrane permeability is a critical factor that influences the bioavailability of a drug. Small molecule drugs generally cross the membrane via a mechanism of passive diffusion, while peptide drugs translocate across the membrane through a complex mechanism. One of our focuses is to understand the mechanism of membrane translocation of drug like molecules, including peptides and peptidomimetics using atomistic modelling and simulations. We have developed several in silico models with different level of resolutions and complexities that can be used for rapid screening of different drug molecules. For small molecule drugs, we use the atomistic lipid membrane models to accurately compute the free energy barrier along the translocation pathway. For peptides and peptidomimetics, simple membrane models are used to identify important metastable states along the translocation pathway. The final objective is to develop useful molecular parameters/descriptors that can predict the membrane permeability of drug like molecules.

BII_EarlyCareerResearchers-MBDD-figure3

Figure 3 – In silico models with various resolutions for the cytoplasmic membrane.

Alfatah Mohammad - Aging Biology Intervention Research

Our group expertise is in functional biology, chemical genetics, and high throughput screening for several phenotypic and experimental conditions. We screen the chemical libraries (small molecules, natural products, and FDA-approved drugs) to identify the interventions for aging. We combine our powerful approaches with multilayer functional analysis and identify the genes, proteins, and biological processes involved in the biology of aging and age-associated pathologies. Our group is also utilizing discovery-driven functional and chemical screening approaches to systematically identify the novel antifungal compounds and map the biological process landscapes of human fungal pathogenesis.

Aging

Aging population rapidly growing worldwide. Aging is the biggest risk factor for several human chronic ailments, including cancer, neurodegeneration, heart disease, diabetes, cognitive impairment and immune system decline (Figure 1). Aging is characterized by a progressive loss of physiological integrity, cellular functions and metabolic signaling. Such biological changes eventually lead to the prevalence of age-related pathologies, thereby compromise human health throughout life. Recent research in eukaryotic different model systems from single-celled yeast to nematode worms, fruit flies, mice and humans, has shown that aging mechanisms are conserved and delay aging is feasible by interventions including caloric restriction and drug administration. Our lab using budding yeast Saccharomyces cerevisiae as a model organism for study aging. The benefits of studying aging in yeast include a short generation time, a tractable life span, a genome-wide knockout library, its amenability to high-throughput functional assays and conservation of genes and pathways that uncover novel insights into human aging and interventions.

BII_Research-BSFD-ABIR-Figure-1

Figure 1 – Aging associated chronic diseases and fungal infections.

We are identifying antiaging compounds by screening the small molecules, natural products, and FDA-approved drugs repurposing. We have developed a robust and sensitive high throughput screening method for the identification of antiaging compounds. The antiaging compounds identified from the screen is further characterizing to understand their mechanism of action. We investigate the mechanism of antiaging compounds by target-based and non-target-based approaches (Figure 2). In target-based mechanism identification, we are directly testing the effect of antiaging compounds on the known hallmarks of aging, such as nutrient signaling, cellular stress, autophagy, mitochondrial integrity, and genome stability. In the non-target-based approach, we perform transcriptomics, proteomics, metabolomics, and phenotypic analysis and uncover the genes, proteins, and biological processes involved in aging interventions. Since several biological processes are incredibly dynamic, including their regulation, we comprehensively investigating antiaging action to understand the functional interactions at different biological layers. Antiaging compounds identified in yeast will be validated in human cells lines and different model systems like nematodes, flies and mice. In addition, we will perform the integrated analysis of multi-omics data to map the functional interactions of aging processes. This system biology-based approach would potentially enable us to identify the biological signature of antiaging compounds and novel aging biomarkers.

BII_Research-BSFD-ABIR-Figure-2

Figure 2 – Schematic representation of target and non-target- based approaches for identification of mechanisms of antiaging compounds.

HUMAN FUNGAL PATHOGENS

Fungal infections are widespread and rarely harmful for infected patients. However, invasive fungal infections are life-threatening, with mortality rates near 50% worldwide. The incidence of fungal infections is rising due to the increasing use of immunosuppressive drugs to treat organ transplant rejection, autoimmune disease, cancer, and growing immunocompromised individuals, particularly the aging population. Older people are associated with a progressive decline of physiological integrity and compromised immune systems that often accelerate invasive fungal infections. Candidiasis is the major fungal infection in the aged population largely caused by the pathogenic yeast species Candida. The primary causative agent of candidiasis is Candida albicans, even though the new Candida pathogens are emerging like C. auris, C. tropicalis, C. glabrata, C. parapsilosis, C. lusitaniae and C. krusei. Only three classes of antifungal drugs, polyenes (amphotericin B), azoles (fluconazole) and echinocandins (caspofungin), are available for the treatment of invasive fungal infections. The main reasons for the lack of effective antifungals include that fungal and human cells are functionally similar, leaving very few pathogen-specific drug targets. Moreover, fungal pathogens rapidly adapt to treatments and develop tolerance to antifungal drugs. In addition to the dearth of therapeutic options and drugs tolerance, the major antifungals are limited in use owing to their toxicity and severe side effects. Therefore, discovering potent antifungal drugs while maintaining low toxicity is an important medical need for invasive candidiasis therapy.

Our lab aim is to discover potent antifungal drugs for the treatment of invasive fungal infections. However, effective treatment is only possible if multiple virulence factors are inhibiting simultaneously. Therefore, the critical challenge in fungal interventions research is identifying inhibitors that target various virulence factors. Moreover, understanding all the biological players of pathogenicity is a crucial requirement to improve antifungal therapy further. Our lab is systematically screening the chemical libraries to identify the inhibitors for various virulence factors of different Candida species (Figure 3). We identify the inhibitors for various pathogenic factors like yeast cells, hyphal development and biofilms in favourable and stress conditions. We further elucidate the mechanism of action of inhibitors by functional analysis approaches and mapping the biological process of pathogenesis. We are unravelling the mechanism of action through concerted, cohesive efforts, including transcriptomics, proteomics, metabolomics and chemical genetics interaction analysis. We will provide the much-needed groundwork to identify the potent antifungal compounds and discover the specific virulence genes, proteins and biological pathways used to diagnose invasive fungal infections.

BII_Research-BSFD-ABIR-Figure-3

Figure 3 – Schematic representation of approaches to identify the human fungal pathogens virulence factors inhibitors and biological process of pathogenesis.